Blueprint Medicines Corp (NAS:BPMC)
$ 96.53 -1.09 (-1.12%) Market Cap: 6.13 Bil Enterprise Value: 5.94 Bil PE Ratio: 0 PB Ratio: 19.54 GF Score: 81/100

Blueprint Medicines Corp to Host Investor Event and Webcast to Review Initial Data from the PIONEER Trial Presented at ASH Transcript

Dec 09, 2019 / 01:30AM GMT
Release Date Price: $70.37 (-10.33%)
Jeffrey W. Albers
Blueprint Medicines Corporation - CEO, President & Director

First off, on behalf of all the employees of Blueprint Medicines, want to thank all of you for sharing a Sunday evening with all of us, and I also want to welcome those of you participating on the webcast.

As always, we'll be making forward-looking statements and refer you to our website or the SEC filing documents and fully disclaim any obligation to update those forward-looking statements.

Agenda-wise, I'll start off with some brief introductory comments, then I'm going to turn it over to Dr. Dan DeAngelo from Dana-Farber and Harvard, who were thrilled to join us tonight. He's an investigator on all 3 of the trials in systemic mastocytosis with avapritinib. Then Andy Boral will talk a little bit about our development plan and pull the data together, and then we'll close and really focus our time together for Q&A before I wrap it up for -- with closing remarks. I've been told that I have to stick strictly to one hour, so we'll try to cover all of our comments within 40, 45 minutes to leave time for

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot